Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“Robust and sustained reductions in both variables were evident for the observed patient population during a 3-year metreleptin treatment period (-2.1% ± 0.5% [mean ± SE ] and -35.4% ± 13.7% [mean ± SE], respectively).”
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists • 2011 | View Paper
Help us improve supp.ai, we'd love to hear your feedback:Submit Feedback